News
Quotient Biodiagnostics Signs Agreement with Blood Centers of America - March 01, 2010
AFFILIATED CENTERS ACCOUNT FOR 30 PERCENT OF NATION’S TRANSFUSION REQUIREMENTS
NEWTOWN, Penn. (March 1, 2010) - Quotient Biodiagnostics, Inc., today announced that it has entered into an agreement with Blood Centers of America (BCA) as a preferred vendor. BCA will actively promote Quotient’s product line to its 38 blood center member organizations, which account for 35 percent of the nation’s transfusion requirements. The deal will include Quotient’s first 15 monoclonal antibodies in its proprietary line of manual transfusion diagnostics as well as future products when approved by the FDA and available.
Quotient Receives FDA Approval - October 19, 2009
Initial Line Of Transfusion Diagnostic Products Will Pave Way For Future Innovation
NEWTOWN, Penn. (October 19, 2009)—Quotient Biodiagnostics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its biologics license application (BLA) for the first 15 monoclonal antibodies in its proprietary line of transfusion diagnostics. These products are for use by blood donor centers, reference laboratories, and hospitals nationwide to type and screen blood.
Quotient Biodiagnostics Poised to Enter U.S. Reagent Market - August 05, 2009
Bill Brady and Michael Hannan Added to Senior Management Team
NEWTOWN, Penn. - Quotient Biodiagnostics (Quotient) today announced the appointment of Michael (Mick) Hannan as Vice President, Marketing & Commercial Development and Bill Brady, as Vice President, Sales. They join Jeremy Stackawitz, President and CEO of Quotient and John Allan, Managing Director of Alba Bioscience to form the senior management team at Quotient.
Quotient Bioscience Group Forms New Biodiagnostics Division - April 07, 2009
Appoints Jeremy Stackawitz as President and CEO of Quotient Biodiagnostics
CAMBRIDGESHIRE, UK - Quotient Bioscience Group Limited (“Quotient Bioscience”), a leading European provider of analytical and safety evaluation services and products for bioscience and sport, today announces the formation of Quotient Biodiagnostics, a separately managed operation within the Quotient Bioscience Group responsible for the Group’s interests in the diagnostics market. The formation of the new division will allow Quotient Bioscience to build on the success of Alba Bioscience, Quotient Bioscience’s existing diagnostics business which is focused on the manufacture and sale of blood-typing reagents and systems for the OEM (Original Equipment Manufacturers) market. Alba Bioscience was acquired by Quotient Bioscience in August 2007.
Events
09/15/10 - 09/16/10
Michigan Association of Blood Banks
TBD
09/21/10 - 09/22/10
Indiana State Association of Blood Banks
The Fountain - Indianapolis, IN
09/29/10 - 09/29/10
Kentucky Association of Blood Banks
American Red Cross Center - Louisville, KY
10/08/10 - 10/12/10
AABB Annual Conference
Convention Center - Baltimore, MD